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Summary Linkage disequilibrium (LD) analysis to reﬁne a region associated with lung cancer
progression on chromosome 1p34 identiﬁed a 106 kb LD block that includes MYCL1, TRIT1 (tRNA
isopentenyltransferase 1) and MFSD2 (major facilitator superfamily domain-containing 2). Case-
only association study on SNPs mapping in TRIT1 and MFSD2 indicated that the rare Leu allele
(frequency: 0.04) of the TRIT1 Phe202Leu variation predicts short survival as compared to the
common Phe/Phe genotype (hazard ratio (HR) = 1.7; 95% CI, 1.03—2.86; P = 0.039) in 335 Italian
lung adenocarcinoma samples. A replication study in an independent population of 246 Norwe-
gian lung cancer patients conﬁrmed the signiﬁcant association of the Phe202Leu polymorphism
with patients’ survival, but the rare allele was associated with better survival rate (HR = 0.5;
95% CI, 0.26—0.91; P = 0.023). The rare allele of TRIT1 Phe202Leu SNP was ∼seven-fold more
frequent in Asian than in Caucasian subjects and three additional SNPs in the TRIT1 and MFSD2
genes showed ethnic differences in allelic frequencies. These results suggest that polymor-
phisms in the MYCL1 LD region affect lung cancer survival but that the functional element(s)
may show population-speciﬁc patterns.
© 2006 Elsevier Ireland Ltd. All rights reserved.
∗ Corresponding author. Tel.: +39 0223902642;
fax: +39 0223903237.
E-mail address: tommaso.dragani@istitutotumori.mi.it
(T.A. Dragani).
1. Introduction
A single nucleotide polymorphism (SNP) affecting an EcoRI
site in the second intron of the MYCL1 (previous symbol:
L-myc) gene was found to be associated with patients’
outcome in lung cancer with contradictory reports [1—5].
0169-5002/$ — see front matter © 2006 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.lungcan.2006.10.023
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Our recent meta-analysis revealed a signiﬁcant association
between the intronic MYCL1-EcoRI variant and lymph node
metastasis, distant metastasis, and clinical stage of lung
cancer patients [6], supporting the hypothesis that genetic
variation in either MYCL1 or a ﬂanking gene determines lung
tumour progression. MYCL1 is frequently ampliﬁed and over-
expressed in small-cell lung cancer but not in a broad range
of lung tumour histotypes [7], and no coding polymorphism
in this gene was found to be associated with lung tumour
prognosis or prognostic factors [8]. Thus, the ﬁndings of
the meta-analysis are likely explained by linkage disequilib-
rium (LD) of the MYCL1-EcoRI polymorphism with a nearby
responsible gene.
Here, we report LD analysis of ∼330 kb on human chro-
mosome 1p34 and identiﬁcation of a ∼106 kb region in LD
with the MYCL1-EcoRI polymorphism which contains two
genes that strongly affect tumour phenotypes: TRIT1, which
is involved in post-transcriptional modiﬁcation of tRNA
molecules, and MFSD2, which encodes a putative transmem-
brane protein.
2. Materials and methods
2.1. Patients and tissue samples
Patients series included 335 lung adenocarcinoma (ADCA)
patients enrolled at Istituto Nazionale Tumori (Milan, Italy),
246 non-small cell lung cancer (NSCLC) patients from Nor-
way (described in [9]), and 92 healthy non-cancer subjects
recruited from Zhejiang, China. All cases were patholog-
ically documented and personal ﬁles were recorded to
obtain clinical data (Table 1). Written informed consent
was obtained from the participating patients and the use of
blood samples and clinical data were in accordance with the
ethical committees in the respective country. Genomic DNA
was extracted from peripheral blood with: the automatic
DNA extractor Extragen 8C (Talent, Trieste, Italy) (Italian
samples); phenol/chloroform (Norwegian samples), and the
DNA Mini kit (Qiagen, Valencia, CA) (Chinese samples).
Total RNA was extracted with the RNeasy Midi kit (Qia-
gen) from 20 samples of normal lung tissue and 20 samples
of lung tumour tissue of Italian lung ADCA patients who
underwent surgical resection at Istituto Nazionale Tumori.
Equal amounts (1g) of lung normal RNAs and lung tumour
RNAs were pooled and the two RNA pools were reverse-
transcribed with the SuperScript® First-Strand Synthesis
System (Invitrogen, Carlsbad, CA).
2.2. Selection of SNPs and genotyping
SNPs mapping in a ∼330 kb region centered on MYCL1
were searched in the NCBI public database (http://www.
ncbi.nlm.nih.gov/SNP/) and ﬁrst validated on a subgroup of
50 Italian patients by pyrosequencing analysis on a PSQ96MA
system (Biotage AB, Uppsala, Sweden). SNP-containing frag-
ments were PCR-ampliﬁed, followed by pyrosequencing
analysis according to the manufacturer’s instructions using
speciﬁc primers. Markers conﬁrmed as polymorphic were
genotyped on Italian lung ADCA patients to assess pairwise
LD between markers. Data on genotypes of 4 MYCL1 SNPs
have been reported [5,8].
Table 1 Characteristics of Italian and Norwegian lung can-
cer patients
Subject characteristics Italians Norwegians
Number of subjects 335 246
Median age (years) 63.0 66.0
Gender
Male 257 174
Female 78 72
Smoker status
Never 45 16
Ever 279 230
Histologya
ADCA 335 106
SQCC 88
LCC 42
Others 10
Lymph node statusb
N0 191 173
N1 111 73
Clinical stage
I 162 160
II 61 44
III 60 42
IV 27 0
Follow-up (months)c 69.1 (n = 122) 74.0 (n = 90)
a ADCA, adenocarcinoma; SQCC, squamous cell carcinoma;
LCC, large cell carcinoma.
b N0, absence of nodal metastasis; N1, presence of nodal
metastasis.
c Median for patients alive at the end of follow-up.
2.3. Analysis of mRNA expression in human lungs
Quantitative real-time PCR ampliﬁcation was carried out
using 0.5l of a template cDNA pool from normal or tumour
lung tissue, 12.5l of 2X QuantiTect SYBR Green PCR Master
Mix (Qiagen, Valencia, CA), and 0.3M gene-speciﬁc intron-
spanning primers (MFSD2: 5′-ccttgtttccaggacctcaa-3′ and
5′-aagtaggcgattggctcaga-3′; MYCL1: 5′-cgagagcccaagcgact-
3′ and 5′-tgatggatggagatgtggaa-3′). Reactions were run on
an ABI GeneAmp 7900 sequence detection system (Applied
Biosystems, Foster City, CA). The human HMBS gene (Gen-
Bank accession # NM 000190) was ampliﬁed with primers
5′-aggatgggcaactgtacctg-3′ and 5′-gcctaccaactgtgggtcat-3′
as a housekeeping control for possible differences in cDNA
amounts. Samples were analysed in triplicate in each experi-
ment. Relative differences were calculated according to the
comparative Ct method using the normal lung cDNA pool for
calibration.
2.4. Sequencing analysis of TRIT1 and MFSD2
coding regions
Complete coding regions of TRIT1 and MFSD2 were
sequenced from normal DNA of Italian lung ADCA patients
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to search for germ-line functional SNPs. All exons were
analysed using MassARRAY technology, except for MFSD2
exons 4 and 5, which were directly sequenced. PCR primers
were designed in ﬂanking intronic regions or untranslated
regions to amplify products not exceeding 600 bp. PCR
primers for MassARRAY analysis were modiﬁed by addition
of a 5′-tail speciﬁc for the T7 promoter (forward primer:
5′-cagtaatacgactcactatagggagaaggct-3′) or the SP6 pro-
moter (reverse primer: 5′-cgatttaggagacactatagaagagaggct-
3′). Analysis by MassARRAY was carried out at Methexis
Genomics (Gent, Belgium) as described [10].
2.5. Assay for isopentenyladenosine activity of
TRIT1 alleles
TRIT1 encodes tRNA isopentenyltransferase, which catalyzes
the formation of the modiﬁed base N6-isopentenyladenosine
(i6A) in position 37 of tRNA molecules that bind
codons starting with uridine [11,12]. TRIT1 alleles were
tested for functional activity in the yeast strain MT-8,
which has defective tRNA-isopentenyltransferase activity
and synthesizes tRNAs lacking the isopentenyl-adenosine
(i6A) modiﬁcation, as compared with yeast strain H57,
which produces an active tRNA-isopentenyltransferase
gene. Yeast transformation and i6A analysis were car-
ried out as described [12]. The TRIT1Phe202 allele was
obtained by ampliﬁcation of a cDNA pool of normal
lung tissue with primers 5′-caacggaccctacctcttgt-3 and 5′-
cacctttccaaaggccact-3′ and cloned into the yeast expression
vector pYES2.1/V5-His-TOPO (Invitrogen). The TRIT1Leu202
allele was generated by in vitro mutagenesis with the
QuickChange®II Site-directed Mutagenesis Kit (Stratagene)
using the pYES2.1/TRIT1Phe202 vector as template and spe-
ciﬁc primers that allowed substitution of nucleotide 620
(based on the annotated sequence GenBank accession
# NM 017646) from thymine to adenine (sense primer
5′-gaatctctcatagtgaattactccatcgtcaacatacgga-3′; antisense
primer 5′-tccgtatgttgacgatggagtaattcactatgagagattc-3′).
2.6. Statistical analysis
Pairwise LD was evaluated calculating D′ and r2 as described
[13]. LD values were graphed using the Java LINkage disequi-
librium plotter (JLIN) (www.genepi.com.au/projects/jlin).
Consistency of genotype frequencies with the Hardy—
Weinberg equilibrium was tested for each SNP locus using
a contingency table of observed versus predicted genotype
frequencies [14]. The Kaplan—Meier product-limit method,
the log-rank test, and the Cox regression model were used
to evaluate the effect of the SNP genotypes on overall sur-
vival [15,16]. Median time intervals were estimated by the
life-table method. Statistical procedures were carried out
with SPSS 10.1 (SPSS Inc., Chicago, IL) software.
3. Results
3.1. LD extends over 106kb around MYCL1
The LD pattern of the chromosomal region containing
the MYCL1 gene was analysed in an Italian population
Fig. 1 LD pattern across the MYCL1 chromosomal region. D′
values for pairwise LD between each marker are represented
in the grey scale, from black (D′ = 1) to white (D′ = 0). Spacing
of markers and the locations of the genes across the genomic
region are shown at the top of the ﬁgure. The region from TRIT1
to MFSD2 shows a block of LD.
of lung ADCA patients, using SNPs to identify the genes
in LD with the MYCL1-EcoRI polymorphism. A region of
∼330 kb spanning from 39.98 to 40.31Mb and centered
on the MYCL1 gene was selected for this analysis and
the genes included were: peptidyl-prolyl cis-trans iso-
merase E (PPIE); bone morphogenetic protein 8 precursor b
(BMP8B); tRNA-isopentenyltransferase (TRIT1); major facil-
itator superfamily domain containing 2 (MFSD2); adenylyl
cyclase-associated protein 1 (CAP1); and palmitoyl-protein
thioesterase 1 precursor (PPT1) (Fig. 1). 4 MYCL1 SNPs were
known [5,8] and 15 SNPs in the other genes were selected
and then validated in a subgroup of 50 Italian individuals;
5 SNPs were excluded from the analysis because they were
not polymorphic, indicating that the possible rare allele had
a frequency lower than 0.01 in the Italian population and
was not detected. LD analysis was carried out on a ﬁnal
group of 14 polymorphisms, which included three coding
variants: MYCL1-Ser362Thr, TRIT1-Phe202Leu, and TRIT1-
Pro11Pro (Table 2).
These 14 SNPs, which showed frequencies of the rare
allele ranging from 0.04 to 0.45 (Table 2), were genotyped
in 103 Italian lung ADCA patients. No deviation from the
Hardy-Weinberg equilibrium was observed. Pairwise LD anal-
ysis showed that MYCL1-EcoRI (rs3134613) maintained strong
LD (D′ > 0.8, Fig. 1) with both its ﬂanking genes, i.e., TRIT1
and MFSD2, whereas LD was no longer displayed beyond
these genes in either direction (Fig. 1). Signiﬁcant LD was
detected also between TRIT1 and MFSD2 over a region of
106 kb. Other blocks of strong LD were identiﬁed between
PPIE and BMP8B over a region of 37 kb and between SNPs
in genes CAP1 and PPT1, which are 32 kb away (Fig. 1).
These ﬁndings restricted the region in LD with MYCL1-
EcoRI polymorphism to a block of 106 kb containing the
genes TRIT1 and MFSD2 in addition to the proto-oncogene
MYCL1.
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Table 2 SNPs used for analysis of LD in the MYCL1 region
Gene SNP accession # SNP type Nucleotide changea Amino acid change Frequency of the
rare allele
PPIE rs580699 intron G39979097A 0.34
BMP8B rs2248992 intron T40015629C 0.25
TRIT1 rs3738671 exon5 A40088475T Phe202Leu 0.04
rs6680378 intron T40096684C 0.40
rs3845570 exon1 G40121718A Pro11Pro 0.40
MYCL1 ss61465381 3′UTR G40134371C 0.24
rs3117086 3′UTR G40135048C 0.17
rs3134614 exon2 C40135641G Ser362Thr 0.10
rs3134613 intron A40137390C 0.45
MFSD2 rs1492701 intron C40194405G 0.19
CAP1 rs3131686 intron A40279809G 0.12
rs3131666 intron A40306482T 0.19
rs7300 3′UTR G40310688A 0.05
PPT1 rs1126973 3′UTR T40311663C 0.17
a Contig position is preceded by the common allele and followed by the rare allele of the polymorphism.
3.2. TRIT1 and MFSD2 are downregulated in lung
ADCAs
We previously showed that TRIT1 mRNA is expressed in nor-
mal lung with a complex pattern of alternatively spliced
variants and that its expression levels are downregulated
∼6- to 14-fold in lung tumour tissue [12]. Similar analysis of
MYCL1 and MFSD2 using quantitative real-time PCR on pools
of normal and tumour lung tissue revealed no detectable
MYCL1 mRNA levels in either normal or ADCA tissue, sug-
gesting that MYCL1 is not a likely lung cancer progression
modiﬁer gene, whereas MFSD2 was expressed in normal lung
parenchyma and downregulated in lung ADCA tissue. Indeed,
analysis of three independent experiments indicated that
Ct values of MFSD2 in pooled tumour versus normal sam-
ples were 3.35± 0.5 (mean± S.E.), indicating a ∼10-fold
lower transcript abundance in lung ADCAs.
3.3. TRIT1 Phe202Leu is associated with patients’
survival
To test whether germ-line variants in the candidate genes
might underlie the observed differences in lung cancer pro-
gression, the entire coding regions of TRIT1 and MFSD2 were
screened for functionally relevant coding polymorphisms in
addition to those reported in the public databases. The anal-
ysis was carried out on two subgroups of Italian lung ADCA
patients, each consisting of 12 samples selected for favor-
able (clinical stage ≥3 and follow-up ≥2 years) and poor
(clinical stage ≤2 and follow-up <1 year) prognosis. Thus,
direct sequencing of genomic DNA of 24 patients to identify
SNPs with a frequency of the rare allele >0.02 conﬁrmed
the presence of the known TRIT1 coding polymorphisms
rs3845570 (Pro11Pro) and rs3738671 (Phe202Leu) mapping in
exon 1 and 5, respectively, but did not identify new coding
variations in this gene (Table 2). SNP rs3845570 is a synony-
mous coding SNP (Pro11Pro) in exon 1 of the TRIT1 gene;
however, in the shorter lung-speciﬁc isoform (AY702933),
the rs3845570 SNP is located in the 5′-UTR region, 25-bp
upstream the alternative ATG codon [12]. Coding SNPs were
not detected in MFSD2.
TRIT1 and MFSD2 SNPs in Italian lung ADCA patients were
tested for an association with clinical parameters. No devi-
ation from the Hardy—Weinberg equilibrium was observed
at any marker. No signiﬁcant association with nodal sta-
tus, clinical stage or patients’ survival was found for the
intronic rs6680378 and the exonic rs3845570 of the TRIT1
gene, or for intronic rs1492701 of the MFSD2 gene (not
shown). On the other hand, the TRIT1 Phe202Leu variant
showed a signiﬁcant association with patients’ survival. Due
to its low frequency (0.04), the Leu variant was found only
in the heterozygous state and no individual carrying the
Leu/Leu genotype was identiﬁed. Analysis of survival rates
showed a signiﬁcant association of the Leu202 allele with
shorter survival: median survival time was 44.0 months for
Phe/Phe individuals and 23.4 months for Phe/Leu patients
(P = 0.039, log-rank test; Fig. 2A). Cox proportional hazard
analysis of survival, adjusted for sex, smoking, age at diag-
nosis (in decades), nodal status, and clinical stage showed
that patients carrying the Phe/Leu genotype had a poorer
survival than patients with the common Phe/Phe genotype
(HR, 1.7; 95% CI, 1.03—2.86; P = 0.039; Table 3).
The association study was replicated in an independent
Caucasian population from Norway. Unlike the Italian
samples, which were all ADCA in histotype, Norwegian
samples included squamous cell carcinomas and large cell
carcinomas in addition to ADCAs (Table 1). Other parameters
were slightly different between the two study populations
(Table 1). The Phe202Leu SNP of the TRIT1 gene showed a
frequency of the rare Leu allele similar to that observed
in the Italian population (i.e., 0.06 versus 0.04) and a
signiﬁcant association with lung cancer patients’ survival
(Table 3); however, the Leu202 allele, which was associated
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Fig. 2 Kaplan—Meier survival curves of TRIT1-Phe202Leu
polymorphism in (A) Italian or (B) Norwegian lung cancer
patients. The curves of patients with the Phe/Phe (Italians,
n = 288; Norwegians, n = 218) or Phe/Leu (Italians, n = 28; Norwe-
gians, n = 28) genotype are shown. Follow-up is shown truncated
at 60 months. Small crosses indicate censored observations.
Log-rank analysis indicates a signiﬁcant difference between
curves (Italians, P = 0.039; Norwegians, P = 0.037).
with poor survival in Italians, showed an opposite trend in
Norwegian lung cancer patients. Indeed, median survival
times of Phe/Leu and Phe/Phe patients were 96.5 and 36.9
months, respectively (P = 0.037, log-rank test; Fig. 2B),
and Cox proportional hazard analysis of survival, adjusted
for sex, smoking, age at diagnosis (in decades), nodal
status, and clinical stage showed that patients carrying the
Phe/Leu genotype had a better survival than patients with
the common Phe/Phe genotype (HR, 0.5; 95% CI, 0.26—0.91;
P = 0.023; Table 3).
3.4. Phe202Leu TRIT1 alleles have similar
biochemical activity
The biochemical activity of the two TRIT1 alleles was com-
pared in a yeast complementation assay. Ampliﬁcation of
TRIT1 from a pool of human normal lung parenchyma pro-
duced only the full-length transcript encoding the common
Phe variant, conﬁrming the low frequency of the Leu variant.
The rare transcript was obtained by in vitro mutagenesis
and vectors expressing TRIT1 variants were transformed in
the MT-8 yeast strain, which synthesizes tRNAs devoid of
isopentenyladenosine (i6A). HPLC and mass spectrometry
analysis of tRNAs extracted from control and transformed
yeast strains revealed no signiﬁcant differences between
the two alleles. Indeed, both variants were functionally
active and produced similar amounts of i6A (1.43± 0.41 and
1.46± 0.36 pmol/g tRNA for the Phe and Leu allele, respec-
tively), which were comparable to i6A levels measured in the
wild-type H57 yeast strain (1.81± 0.40 pmol/g tRNA).
3.5. Ethnic differences in allele frequency at
TRIT1 and MFSD2 genes
Genotyping of the Phe202Leu variation in a small group
(n = 92) of Chinese non-cancer controls revealed a higher
frequency of the rare Leu202 allele (0.28) as compared to
the Italian (0.04) or Norwegian (0.06) samples. To verify
and extend these ﬁndings on ethnic differences, we have
extracted the HapMap (http://www.hapmap.org/) genotype
data of SNPs located in TRIT1, MYCL1, or MFSD2 genes.
The frequency of the Leu202 allele was 0.03 in Caucasian
(CEPH, n = 90) and 0.32 in Asian (JPT +CHB, n = 90) subjects
(Table 4), thus our ﬁndings conﬁrm HapMap data.
Comparison of allele frequencies between Caucasian and
Asian subjects showed signiﬁcant differences (−log P > 5.0,
2-test) at SNPs rs3768308, rs3738671 (Phe202Leu), and
Table 3 Association between TRIT1 Phe202Leu polymorphism and survival of Italian or Norwegian lung cancer patients
Genotype Number of subjects Eventsa Hazard ratiob 95% CI P
Italians
Phe/Phe 288 163 1
Phe/Leu 28 20 1.7 1.03—2.86 0.039
Norwegians
Phe/Phe 218 129 1
Phe/Leu 28 11 0.5 0.26—0.91 0.023
a Number of deaths within 60 months of follow-up.
b Adjusted for sex, smoking, age at diagnosis (in decades), N status (N0 or N > 0), and clinical stage (stage 1 or stage > 1).
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Table 4 Type and allele frequency of SNPs in TRIT1 or MFSD2 genes by ethnicitya
Gene SNP Chromosome
position (kb)b
Gene location Allelesc Frequency of the rare allele −log P
Caucasians Asians
TRIT1 rs7315 40079 3′-UTR A/G G (0.42) A (0.34) 3.2
TRIT1 rs3768308 40084 intron T/C C (0.02) C (0.31) 10.9
TRIT1 rs3738671 40088 Phe202Leu T/A A (0.03) A (0.31) 10.6
TRIT1 rs2294814 40092 intron A/C C (0.49) A (0.38) 1.5
TRIT1 rs12086005 40095 intron C/A A (0.00) A (0.02) 1.1
TRIT1 rs12028138 40097 intron T/C C (0.00) C (0.20) 7.8
MYCL1 rs3134614 40136 Ser362Thr G/C C (0.11) C (0.00) 4.3
MYCL1 rs3134613 40137 intron (EcoRI) T/G G (0.46) G (0.45) 0.0
MFSD2 rs12072037 40193 5′-region C/A A (0.01) C (0.49) 23.0
MFSD2 rs4360512 40195 intron C/T T (0.00) T (0.03) 1.7
MFSD2 rs12747592 40200 intron C/T T (0.04) T (0.00) 2.1
MFSD2 rs3103778 40206 intron G/A A (0.37) A (0.49) 1.4
a Genotypes were extracted from the HapMap data (http://www.hapmap.org/).
b According to the Ensembl database (http://www.ensembl.org/Homo sapiens/index.html).
c Common/rare in Caucasians.
rs12028138 of TRIT1 gene, and rs12072037 of MFSD2 gene.
On the other hand, MYCL1-EcoRI SNP (rs3134613) did not
show different allele frequencies between Asian and Cau-
casian subjects (Table 4).
4. Discussion
The MYCL1-EcoRI polymorphism was the ﬁrst germ-line
variation reported to be associated with cancer patients’
prognosis. Although contrasting results have been described
on the effects of this SNP, a meta-analysis pointed to
its signiﬁcant role in the modulation of cancer prog-
nostic parameters, in particular lymph node status and
clinical stage of lung cancer patients [6]. This ﬁnd-
ing is most likely explained by LD of this SNP with a
nearby functional polymorphism that affects lung cancer
progression.
Our case-only association study on Italian lung ADCA
patients identiﬁed a 106 kb LD block including the proto-
oncogene MYCL1 and the two ﬂanking genes TRIT1 and
MFSD2, suggesting the candidacy of these genes as likely
lung cancer progression modiﬁers. Our LD results are in
agreement with those reported by the HapMap project
that also shows a signiﬁcant LD extending between the
TRIT1 and MFSD2 genes in Caucasian (36 informative SNPs)
as well as in Asian (37 informative SNPs) subjects (not
shown).
MYCL1 is reported to be preferentially ampliﬁed in small
cell lung cancer but not in other lung cancer histotypes [7]
and, in fact, we detected no MYCL1 expression in either nor-
mal lung or ADCA tissue, indicating that it cannot explain the
reported prognostic effect. Conversely, TRIT1 and MFSD2 are
expressed in normal lung tissue and downregulated in lung
ADCA samples, suggesting they might play a role as lung
tumour suppressor genes. Consistent with this hypothesis,
we found frequent allelic losses in lung ADCA samples in this
region [12]. TRIT1 catalyzes post-transcriptional modiﬁca-
tion of tRNA molecules and might affect cancer progression
through deregulation of the synthesis of essential proteins.
As for MFSD2, no information is currently available on
its role except its protein product contains several trans-
membrane domains similar to those of other carbohydrates
transporters.
TRIT1 non-synonymous Phe202Leu SNP was signiﬁcantly
associated with worse survival in Italian lung cancer
patients, and the adjusted logistic regression analysis
showed that the effect was independent from lymph node
status or clinical stage. Further analysis of the functional
role of the TRIT1 Phe202Leu SNP in modulating survival
of lung cancer patients was conducted in an independent
group, i.e., Norwegian lung cancer patients whose clinical
and follow-up data were available. The rare Leu202 allele
showed a similar frequency in Italian and Norwegian
patients, but it was signiﬁcantly associated with better
survival in the Norwegian series (Fig. 2B, Table 3), unlike
the Italian population. In the Norwegian series, association
of Phe202Leu SNP in ADCA patients only showed the same
trend without reaching statistical signiﬁcance. Also, a
combined analysis of both populations (ADCA only or all his-
totypes) did not show signiﬁcant associations, as expected
by the opposite trends of the Phe202Leu SNP in the two
populations. Because the small number of Norwegian ade-
nocarcinomas (n = 106), we cannot rule out the possibility
that a larger replication series could conﬁrm the ﬁndings on
Italians.
As a further attempt, we generated haplotypes by the
combination of TRIT1 and MFSD2 SNPs. TRIT1 rs3845570
(Pro11Pro) and MFSD2 rs1492701 SNPs were chosen because
of the relatively high frequency of their rare allele, that
would allow to generate haplotype groups containing a
reasonable high number of patients for association anal-
ysis. Indeed, each of the four possible haplotype groups
contained from 33 to 177 patients; each haplotype group
was compared with the group of patients not carrying
that speciﬁc haplotype for association with lung can-
cer survival, however, no signiﬁcant associations were
detected.
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Whereas false-positive random results cannot be ruled
out entirely to explain these contrasting observations,
results reﬂecting a true effect would support ﬁndings of
the previous meta-analysis on MYCL1-EcoRI polymorphism
pointing to the major role of this chromosomal region in the
control of lung cancer progression. However, contradictory
results of the association studies in the two different popu-
lations argue against the identiﬁcation of TRIT1 Phe202Leu
as the responsible polymorphism, a notion also suggested
by yeast complementation studies indicating comparable
biochemical activity of the two alleles. A similar result
was observed with the intronic KRAS polymorphism whose
RsaI A2 allele showed a signiﬁcant association with disease
survival of lung ADCA patients from two unrelated popula-
tions, but with an opposite trend [17]. Those ﬁndings are
consistent with a role for genetic elements of those regions
in the control of lung cancer progression and patients’
survival, although the functional elements remain to be
identiﬁed.
Association of MYCL1-EcoRI with lung cancer patients’
survival was observed in all of four studies of Asians, but in
none of three studies on Caucasians [6], including a study
in an Italian [5] and a study in a Norwegian series [4].
As frequencies of TRIT1 Phe202Leu SNP and of additional
SNPs in TRIT1 and MFSD2 genes are signiﬁcantly different
among Caucasian and Asian subjects (Table 4), these results
raise the possibility of population-speciﬁc allele frequency
patterns in this chromosomal region, which might involve
also the polymorphism(s) controlling lung cancer progres-
sion, and they may suggest that Caucasian series may have
a low power to detect the effect on survival of the functional
polymorphism in the MYCL1 region.
The LD between TRIT1 and MFSD2 and the tumour sup-
pressor effects exerted by TRIT1 on lung cancer cell lines
in vitro [12] points to their candidacy as lung cancer pro-
gression modiﬁer genes. Polymorphic genetic elements of
the region containing the two genes may control cancer
patients’ survival by ﬁne modulation of their expression
and/or of their isoform pattern. Further studies to iden-
tify regulatory SNPs in this region and to genotype these
SNPs in large lung cancer series, including Asian patients,
are needed to address this point.
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